Skip Navigation


Carcinogenesis Advance Access originally published online on March 7, 2007
Carcinogenesis 2007 28(7):1393-1400; doi:10.1093/carcin/bgm050
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/7/1393    most recent
bgm050v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Wu, Z
Right arrow Articles by Theodorescu, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, Z
Right arrow Articles by Theodorescu, D
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

The role of PTEN in prostate cancer cell tropism to the bone micro-environment

Z Wu, KS McRoberts and D Theodorescu*

Department of Molecular Physiology and Biological Physics, Box 422, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA

* To whom correspondence should be addressed. Tel: +1 434 924 0042; Fax: +1 434 982 3652;Email: dt9d{at}virginia.edu

Little is known about the role of the tumor suppressor gene phosphatase and tensin homolog deleted on chromosome 10 (PTEN) in prostate cancer bone metastasis. To explore this, we used a pTetOn PTEN cell line in which PTEN expression was reconstituted in a PTEN-null bone metastatic human prostate cancer cell line, LnCaP-C4-2. We found that C4-2 cells selectively migrated toward conditioned medium from primary mouse calvaria cells compared with that derived from lung fibroblasts. Further evaluation with conditioned medium from an established mouse calvaria osteoblast cell line and control non-osteoblast cell line indicates that osteoblastic characteristics convey this specific migration to C4-2 cells. We evaluated promiscuously metastatic PC-3 prostate as well as T24T and UMUC-3 bladder cells and found they did not have a specific migratory response to calvaria-conditioned medium as did C4-2. Induction of PTEN expression inhibited the motility of C4-2 cells toward calvaria-conditioned medium but had no effect on migration toward lung-conditioned medium and this inhibitory effect was dependent on the PTEN lipid phosphatase activity. Calvaria- but not lung-conditioned medium induced activation of the small GTPase Rac1. Constitutively active Rac1 but not focal adhesion kinase or Cdc42 could rescue cells from the inhibitory effect of PTEN on cell migration and PTEN induction was observed to inhibit Rac1 activation in response to calvaria-conditioned medium. Our results support the notion that loss of PTEN function in human prostate cancer may specifically facilitate bone rather than other organ metastasis and suggest that Rac1, as a PTEN effector, may contribute to this metastatic tropism.

Abbreviations: FAK, focal adhesion kinase; FBS, fetal bovine serum; PTEN, phosphatase and tensin homolog deleted on chromosome 10; WT, wild type; MEM, minimum essential medium; HA, hemaglutinin; EGFP, enhanced green fluorescent protein; PAK-1, p21 activated kinase 1; PI3K, phosphoinositide 3-kinase; EGF, epidermal growth factor; PDGF, platelet-derived growth factor

Received July 13, 2006; revised February 21, 2007; accepted February 27, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
H. L. Goel, J. Li, S. Kogan, and L. R Languino
Integrins in prostate cancer progression
Endocr. Relat. Cancer, September 1, 2008; 15(3): 657 - 664.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.